An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Therapy for the Treatment of Severe Posttraumatic Stress Disorder
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Methylenedioxymetamfetamine (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Sponsors Lykos Therapeutics
Most Recent Events
- 20 May 2022 Status changed from active, no longer recruiting to completed.
- 14 Aug 2020 Planned End Date changed from 1 Oct 2019 to 18 Aug 2021.
- 14 Aug 2020 Planned primary completion date changed from 1 Oct 2019 to 10 Aug 2021.